NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
09/24/2023
Back to search
Official data from USPTO
AMANO
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
36
Latest update
09/24/2023
Trademark type
Combined
Nice classes
1, 5
Filing date
03/28/2001
Registration date
06/03/2003
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
09/24/2023
Last transaction
09/24/2023
Responsible office
United States Patent and Trademark Office
Status code
800
Official register
Principal Register
First use anywhere
1993-04-00
First use in commerce
1993-04-00
Drawing code
5
Owner type
03
Owner location
Aichi-ken, JP
Examiner
FRENCH, CURTIS
Law office
M60
Current location
GENERIC WEB UPDATE
Mark description
The mark consists of the word "AMANO" in stylized typography.
Holders and representatives
Holders
Amano Enzyme Inc.
Representatives
John E. Lyhus Fitch, Even, Tabin & Flannery, LLP.
Technical classification
Nice Classes
Class 1Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
ENZYME PREPARATIONS FOR USE IN THE MANUFACTURE OF SACCHARIDECONFECTIONERYBAKERY PRODUCTSBEVERAGE PRODUCTSBREWING PRODUCTSDAIRY PRODUCTSFOOD SEASONINGSANIMAL FEEDDIETARY SUPPLEMENTSDIGESTIVE AGENTS AND ANTI-INFLAMMATORY AGENTS; ENZYME S PREPARATIONS FOR USE IN PROTEIN HYDROLYSIS; DIAGNOSTIC ENZYME REAGENTS FOR SCIENTIFIC OR RESEARCH USE
Class 5
ENZYME PREPARATIONS FOR MEDICAL PURPOSESFOR USE IN THE TREATMENT OF DYSPEPSIACORPULENCE AND THROMBOSIS; ENZYME PREPARATIONS FOR VETERINARY PURPOSESFOR USE IN THE TREATMENT OF DYSPEPSIACORPULENCE; DIAGNOSIS ENZYME S REAGENTS FOR CLINICAL OR MEDICAL LABORATORY USE
Publications
History of USPTO decisions and trademark events.
36 publications found
RNL2
REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
09/24/2023
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
09/24/2023
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
09/24/2023
E89R
TEAS SECTION 8 & 9 RECEIVED
03/20/2023
REM2
COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
06/03/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
04/20/2016
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
02/19/2015
NA89
NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
06/12/2013
RNL1
REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
06/12/2013
89AG
REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
06/12/2013
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
06/12/2013
E89R
TEAS SECTION 8 & 9 RECEIVED
05/17/2013
C15A
REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
04/19/2009
PLGL
ASSIGNED TO PARALEGAL
04/16/2009
815F
REGISTERED - SEC. 8 (6-YR) & SEC. 15 FILED
04/09/2009
PAPER RECEIVED
04/09/2009
CFIT
CASE FILE IN TICRS
03/25/2008
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
10/31/2003
AMD7
SEC 7 REQUEST FILED
08/20/2003
PAPER RECEIVED
08/20/2003
R.PR
REGISTERED-PRINCIPAL REGISTER
06/03/2003
PUBO
PUBLISHED FOR OPPOSITION
03/11/2003
NPUB
NOTICE OF PUBLICATION
02/19/2003
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/22/2003
ZZZX
PREVIOUS ALLOWANCE COUNT WITHDRAWN
01/22/2003
PAPER RECEIVED
11/29/2002
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
11/21/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
10/25/2002
PAPER RECEIVED
10/25/2002
CNRT
NON-FINAL ACTION MAILED
04/25/2002
DOCK
ASSIGNED TO EXAMINER
04/23/2002
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
01/10/2002
CNRT
NON-FINAL ACTION MAILED
07/16/2001
DOCK
ASSIGNED TO EXAMINER
07/12/2001
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
07/10/2001
Continuous trademark protection
Get notified about every new filing that threatens AMANO or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.